Kyverna Therapeutics Announces First Patient Enrolled in Phase 1 Clinical Trial of CD19 CAR T-cell Therapy for Lupus Nephritis in the U.S.

KYV-101 is a novel, fully human CD19 CAR T-cell therapy designed for use in patients with B cell-driven autoimmune diseases Phase 1 open-label clinical trial in the U.S. is actively recruiting patients with LN at multiple sites Patients in treatment with KYV-101 for multiple indications…